Brett R Hagen sold $8,135 of KLRS
Chief Accounting Officer at Kalaris Therapeutics, Inc.. 907 shares at an average of $8.97, traded Mar 26, 2025, filed Mar 27, 2025.
Score components
- +15RoleOfficer
- 0Trade size$8k at market
- +10Share of holdings soldSold 32% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-046263, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2025 | SOpen-market sale Common Stock | -907 | $8.97 | $8,135 | 1,925 | Mar 27, 2025 |
Related signals
Other insiders at Kalaris Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | KLRSbuy Kalaris Therapeutics, Inc. | Srinivas Akkaraju director, owner | $5.0M 479,847 shares | +32% | |
| 30Weak | Kalaris Therapeutics, Inc. | Edward Miller General Counsel | $1,068 106 shares | -2% | |
| 30Weak | Kalaris Therapeutics, Inc. | Brett R Hagen Chief Accounting Officer | $967 96 shares | -3% | |
| 30Weak | Kalaris Therapeutics, Inc. | Vikas Sinha See Remarks | $3,053 303 shares | -1% | |
| 30Weak | Kalaris Therapeutics, Inc. | Vikas Sinha See Remarks | $1,226 129 shares | -0% | |
| 30Weak | Kalaris Therapeutics, Inc. | Brett R Hagen Chief Accounting Officer | $342 36 shares | -1% | |
| 30Weak | Kalaris Therapeutics, Inc. | Edward Miller General Counsel | $494 52 shares | -1% | |
| 30Weak | Kalaris Therapeutics, Inc. | Vikas Sinha See Remarks | $431 979 shares | -0% | |
| 30Weak | Kalaris Therapeutics, Inc. | Brett R Hagen Chief Accounting Officer | $146 332 shares | -0% | |
| 30Weak | Kalaris Therapeutics, Inc. | Edward Miller General Counsel | $180 409 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.